Richard D. Lutze

This study shows trametinib causes mitochondrial injury and innate immune activation in mouse hearts, leading to cardiomyopathy and heart failure.

This study identifies ROR-alpha as a critical regulator of the cardiomyocyte transcriptome, including the alpha-1A adrenergic receptor, through genetic and pharmacologic analyses in mice.

This study identifies oseltamivir as a drug that protects against hearing loss in mice caused by cisplatin and noise exposure.

This study tests tizaterkib, an ERK1/2 inhibitor, for treating noise-induced hearing loss in mice, finding it protects hearing and reduces immune response.

This study shows that trametinib, a MEK1/2 inhibitor, protects mice from cisplatin and noise-induced hearing loss without compromising cisplatin's tumor-killing effects.

This paper shows that knocking out KSR1 in mice protects against cisplatin- and noise-induced hearing loss by inhibiting the MAPK pathway.